Home / News / Pearce IP Blog
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
07 JUL 2023 | IN | CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
01 JUL 2023 | US | Organon and Samsung Bioepis announce launch of Hadlima®, biosimilar to AbbVie’s Humira®...
22 JUN 2023 | JP | ASLAN enters strategic licence with Zenyaku Kogyo to exclusively develop and commercialise novel...
The Full Federal Court handed down its decision this morning in the longstanding dispute as to whether the...
The PBS listing for Chiesi’s Epidyolex®, an oral cannabidiol, was expanded on 1 June 2023 to include treatment of...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
16 JUN 2023 | BR | Bio-Thera Solutions enter agreement for distribution of BAT2206 (ustekinumab biosimilar to...
Katy Perry has appealed a Federal Court decision handed down on 21 April 2023 by Markovic J in Australia (Taylor v...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
01 JUN 2023 | EU | New indication alert: EC approves Novartis’ Cosentyx® (secukinumab) for HS Novartis announced that...
Merck announced positive results in two studies evaluating Keytruda®, its anti-PD-1 therapy. Merck reported that...